# Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)

> **NCT03173742** · PHASE1 · COMPLETED · sponsor: **Insud Pharma** · enrollment: 54 (actual)

## Conditions studied

- Helminthiasis

## Interventions

- **DRUG:** T1, T2, T3
- **DRUG:** T1,T3,T2
- **DRUG:** T2,T1,T3
- **DRUG:** T2,T3,T1
- **DRUG:** T3,T1,T2
- **DRUG:** T3,T2,T1

## Key facts

- **NCT ID:** NCT03173742
- **Lead sponsor:** Insud Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03173742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03173742, "Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03173742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*